Form 4: Phathom Pharmaceuticals CFO Molly Henderson Reports Stock Sale to Cover Tax Obligations

Molly Henderson, CFO and CBO of Phathom Pharmaceuticals, sold 6,583 shares of common stock on January 21, 2025, to cover tax withholding obligations.

Summary

• On January 21, 2025, Molly Henderson, the CFO and CBO of Phathom Pharmaceuticals, sold 6,583 shares of the company's common stock.
• The sale was executed to satisfy tax withholding obligations related to the settlement of restricted stock units.
• The shares were sold at a weighted average price of $6.5883.
• Following the transaction, Henderson directly owns 93,546 shares of Phathom Pharmaceuticals common stock.
• Henderson also indirectly owns 1,911.27 shares through a 401(k).
• Additionally, she acquired 1,973 shares under the employee stock purchase plan in January 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects a routine transaction to cover tax obligations, which is neither particularly positive nor negative.

Positives

• Henderson's participation in the employee stock purchase plan indicates confidence in the company's future.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. This filing indicates that the CFO is managing her personal financial obligations related to equity compensation.

Stakeholder Impact

• The stock sale could have a minor, temporary impact on the stock price due to increased selling pressure, but it's unlikely to be significant given the relatively small volume of shares sold.

Key Dates

Keywords

Phathom Pharmaceuticals, Molly Henderson, stock sale, Form 4, tax obligations, restricted stock units, employee stock purchase plan, insider trading